- Home
- CGTX vs CALC Comparison
CGTX vs CALC Comparison
Compare CGTX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- CALC
- Stock Information
- Founded
- CGTX 2007
- CALC 2011
- Country
- CGTX United States
- CALC United States
- Employees
- CGTX N/A
- CALC N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- CALC Health Care
- Exchange
- CGTX Nasdaq
- CALC Nasdaq
- Market Cap
- CGTX 26.8M
- CALC 25.2M
- IPO Year
- CGTX 2021
- CALC N/A
- Fundamental
- Price
- CGTX $0.37
- CALC $1.55
- Analyst Decision
- CGTX Strong Buy
- CALC Strong Buy
- Analyst Count
- CGTX 5
- CALC 3
- Target Price
- CGTX $7.13
- CALC $16.33
- AVG Volume (30 Days)
- CGTX 595.7K
- CALC 60.3K
- Earning Date
- CGTX 05-06-2025
- CALC 05-12-2025
- Dividend Yield
- CGTX N/A
- CALC N/A
- EPS Growth
- CGTX N/A
- CALC N/A
- EPS
- CGTX N/A
- CALC N/A
- Revenue
- CGTX N/A
- CALC N/A
- Revenue This Year
- CGTX N/A
- CALC N/A
- Revenue Next Year
- CGTX N/A
- CALC N/A
- P/E Ratio
- CGTX N/A
- CALC N/A
- Revenue Growth
- CGTX N/A
- CALC N/A
- 52 Week Low
- CGTX $0.31
- CALC $1.45
- 52 Week High
- CGTX $2.95
- CALC $6.27
- Technical
- Relative Strength Index (RSI)
- CGTX 43.16
- CALC 32.53
- Support Level
- CGTX $0.31
- CALC $1.45
- Resistance Level
- CGTX $0.41
- CALC $1.67
- Average True Range (ATR)
- CGTX 0.04
- CALC 0.15
- MACD
- CGTX 0.01
- CALC -0.01
- Stochastic Oscillator
- CGTX 51.85
- CALC 15.38
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.